Asia Pacific liposome drug delivery market is expected to reach US$ 1,562.92 million in 2027 from US$ 759.81 in 2019. The market is estimated to grow with a CAGR of 9.6% from 2020-2027.
Liposomes are small sphere-shaped artificial vesicles synthesized from cholesterol and phospholipids. They have multiple layers and a diameter range of 0.01 to 5.0 um. They also have hydrophilic and hydrophobic properties which help liposomes to encapsulate hydrophobic and hydrophilic drugs to be delivered to targeted body site. Liposomes provide an assured system for targeted drug delivery and thereby is the factor influencing the Liposome Drug Delivery market size growth. Liposomes are widely used for enclosing all types of drug molecules such as acyclovir, chloroquinediphosphate, paclitaxel, tropicamide, and cyclosporine. Liposomes are used as a drug carrier for drug therapy for many diseases since they are biodegradable and biocompatible. Also, they have many therapeutic properties like anticancer drugs, genetic materials, proteins, vaccines, macromolecules, and thus can be encapsulated in liposomes. The scope of the liposome drug delivery market includes product, technology, application, and region.
Japan Liposome Drug Delivery Market Revenue and Forecasts to 2027 (US$ MN)
- This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.
Market Insights
New Developments in Lipid Composition for Stability and Optimization of Drugs
The pharmaceutical and biotechnology companies are exploring alternative compositions with cholesterol as well as new techniques such as nanotechnology to improve the stability and drug release profiles with the help of encapsulation and other techniques. They are using liposomes for the generation of extracellular vesicles by targeted cells. According to the Department of Pharmaceutics, SPER, JamiaHamdard University, New Delhi, India a current research was done to prolong and sustain the release of erythromycin (ERY) by preparing a solid lipid nanoparticles (SLNs)-based gel formulation for the safe and effective treatment of acne. ERY-loaded SLNs were developed, and various process variables were optimized with respect to particle size, zeta potential, and entrapment efficiency using the Taguchi model. The main aim was to develop ERY-loaded SLNs-based gel with the potential to sustain and delay the release of the drug. The developed gel may be suitable for the treatment of acne. Manufacturers in the liposome drug delivery market are ramping up their R&D activities to unlock new lipid compositions and strategies that help to optimize the drug transport and stability of liposomes. Similar experiments for innovative liposome fabrication are likely to offer growth opportunities for the market players to attain a significant position and grow in the liposome drug delivery market—new development lipid composition for stability and optimization of drugs.
Product- Based Market Insights
Based on product, the liposome drug delivery market is segmented into liposomal doxorubicin, liposomal paclitaxel, liposomal amphotericin B, others. The liposomal doxorubicin segment held the largest share of the market in 2019, whereas the liposomal amphotericin B segment is anticipated to register the highest CAGR in the market during the forecast period.
Asia Pacific Liposome Drug Delivery Market, by Product – 2019 and 2027
- This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.
Technology- Based Market Insights
Based on technology, the liposome drug delivery market has been segmented into stealth liposome technology, non-PEGylated liposome technology, depofoam liposome technology. The stealth liposome technology segment held the largest share of the market in 2019, and continued to register the highest CAGR in the market during the forecast period.
Application- Based Market Insights
Based on application, the liposome drug delivery market has been segmented into fungal diseases, cancer therapy, pain management, viral vaccines, and photodynamic therapy. The cancer therapy segment held the largest share of the market in 2019, and continued to register the highest CAGR in the market during the forecast period
Customize This Report To Suit Your Requirement
You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities
Asia Pacific Liposome Drug Delivery Market: Strategic Insights

- Get Top Key Market Trends of this report.This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.
You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities
Asia Pacific Liposome Drug Delivery Market: Strategic Insights

- Get Top Key Market Trends of this report.This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.
High Rise in Popularity of Liposomes in Drug Delivery
Product launches and approvals are commonly adopted strategies by companies to expand their footprint worldwide and meet the growing demand. The players operating in the liposome drug delivery market adopt the expansion, collaboration, and product launch strategies to enlarge customer base across the world. These strategies allow the players to maintain their brand name globally. For instance, Janssen Biotech, Inc. has given additional funding to support further research under its R&D Collaboration and Option to License Agreement with Dendright Pty Ltd (established by UniQuest, the main commercialization company of The University of Queensland) to develop Dendright's tolerizing immunotherapy for the treatment of patients with rheumatoid arthritis (RA). The collaboration will allow the conduct of a first-in-human safety and tolerability study in the second half of 2017 as a turning point in the development of a new liposomal drug product, DEN-181, which offers the potential to intercept RA at a very early stage.
ASIA PACIFIC LIPOSOME DRUG DELIVERY MARKET SEGMENTATION
By Product
- Liposomal Doxorubicin
- Liposomal Paclitaxel
- Liposomal Amphotericin B
- Others
By Technology
- Stealth Liposome Technology
- Non-PEGylated Liposome Technology
- DepoFoam Liposome Technology
- Lysolipid Thermally Sensitive Liposome (LTSL) Technology
By Application
- Fungal Diseases
- Cancer Therapy
- Pain Management
- Viral Vaccines
- Photodynamic Therapy
Companies Mentioned
- ASTELLAS PHARMA INC.
- JOHNSON AND JOHNSON SERVICES, INC.
- LUYE PHARMA GROUP
- TAKEDA PHARMACEUTICAL COMPANY LIMITED
- Novartis AG
- IpsenPharma
- Gilead Sciences, Inc
- Celsion, Inc.
Asia Pacific Liposome Drug Delivery Market Regional Insights
The regional trends and factors influencing the Asia Pacific Liposome Drug Delivery Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Asia Pacific Liposome Drug Delivery Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

- Get the Regional Specific Data for Asia Pacific Liposome Drug Delivery Market
Asia Pacific Liposome Drug Delivery Market Report Scope
Report Attribute | Details |
---|---|
Market size in 2019 | US$ 759.81 Million |
Market Size by 2027 | US$ 1,562.92 Million |
Global CAGR (2020 - 2027) | 9.6% |
Historical Data | 2017-2018 |
Forecast period | 2020-2027 |
Segments Covered |
By Product
|
Regions and Countries Covered | Asia-Pacific
|
Market leaders and key company profiles |
Asia Pacific Liposome Drug Delivery Market Players Density: Understanding Its Impact on Business Dynamics
The Asia Pacific Liposome Drug Delivery Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Asia Pacific Liposome Drug Delivery Market are:
- ASTELLAS PHARMA INC.
- JOHNSON AND JOHNSON SERVICES, INC.
- LUYE PHARMA GROUP
- TAKEDA PHARMACEUTICAL COMPANY LIMITED
- Novartis AG
Disclaimer: The companies listed above are not ranked in any particular order.

- Get the Asia Pacific Liposome Drug Delivery Market top key players overview
- Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
- PEST and SWOT Analysis
- Market Size Value / Volume - Global, Regional, Country
- Industry and Competitive Landscape
- Excel Dataset



Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Product, Technology, Application, and Country

Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Australia, China, Japan, South Korea
Trends and growth analysis reports related to Life Sciences : READ MORE..
The List of Companies - Asia Pacific Liposome Drug Delivery Market
- ASTELLAS PHARMA INC.
- JOHNSON AND JOHNSON SERVICES, INC.
- LUYE PHARMA GROUP
- TAKEDA PHARMACEUTICAL COMPANY LIMITED
- Novartis AG
- Ipsen Pharma
- Gilead Sciences, Inc
- Celsion, Inc.